Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomira has submitted an investigational new drug application to the FDA for PX-478, a novel inhibitor of a protein that controls genes whose products are important for tumor growth and survival.
Subscribe to our email newsletter
In preclinical studies, PX-478 produced significant tumor regression and growth delay in multiple models of human cancers, including cancers of the lung, breast, prostate, colon, kidney, pancreas and ovary.
“HIF-1 alpha is a drug target that provides a multi-pronged approach for cancer therapy. We believe that PX-478 will be the first small molecule to enter clinical development that acts directly to lower HIF-1 alpha protein levels,” said Dr Lynn Kirkpatrick, chief scientific officer of Biomira.
Upon clearance of the IND, Biomira intends to initiate a phase 1 trial for this compound in the third quarter of 2007.